Information Provided By:
Fly News Breaks for February 21, 2018
ESPR
Feb 21, 2018 | 09:10 EDT
Needham analyst Chad Messer raised his price target on Esperion to $94 and kept his Strong Buy rating. Messer notes that regulatory uncertainty for the company is in the past, while the phase 3 readouts on its Bempedoic Acid products starting next month could disclose further progress toward a "blockbuster opportunity". The analyst says that the readouts are "significantly de-risked" given the lack of any safety signals to date.
News For ESPR From the Last 2 Days
ESPR
Mar 28, 2024 | 10:59 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here
ESPR
Mar 27, 2024 | 10:47 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here